EANM’07 – CME Session III
October 14, 2007, 14:30 – 16:00
Drug Development in Neuropsychiatric Disorders
Moderator: C. Halldin (Stockholm)
Co-Moderator: P. Salvadori (Pisa)
|J. Tauscher (Vienna):
|B. Gulyas (Stockholm):
|J. Seibyl (New Haven):
Upon completion of this course the attendee will be able to:
- Identify the principles of using PET or SPECT for CNS drug development
- Describe ways to use imaging in development of drugs for different disorders such as Schizophrenia
- Describe ways to use imaging in development of biomarkers
A basic problem in the development of novel drugs to be used in the therapy of neuropsychiatric disorders is to find relevant in vitro or in vivo animal models and to be able to extrapolate the results to man. Drug research now benefits from the fast development of functional imaging techniques that trace radiolabeled molecules directly in the human brain. Positron Emission Tomography (PET) and allied techniques use molecules which are labeled with short-lived radionuclides and injected intravenously in experimental animals, human volunteers or patients.
The most straightforward approach is to radiolabel a new potential drug and to trace its uptake, anatomical distribution and binding in brain (microdosing). An indirect approach is to study how the unlabeled drug inhibits specific radioligand binding (receptor occupancy). Furthermore, PET and SPECT may have applications as biomarkers for a disorder such as Alzheimer’s disease in a clinical or research setting.
Drug development, PET, neuropsychiatric disorders, Schizophrenia, Alzheimer’s disease, Parkinson’s disease